The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Victrelis™ (boceprevir) and Hepatitis C

When is Victrelis™ contraindicated?

UPDATE: As of January 2015 Merck announced it will discontinue selling Victrelis in the United States by the end of the year.

The same contraindications that pertain to peginterferon and ribavirin also apply to the Victrelis™ combination treatment. This combination treatment is contraindicated in the following:

  • Pregnant women and men whose female partner is pregnant due to the risks for birth defects and fetal death associated with ribavirin.
  • Coadministration with drugs that are highly dependent on CYP3a4/5 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events including:

Last Updated: January 2015

Merck "Highlights of Prescribing Information - Victrelis" http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf. Retrieved May 18, 2011.

Merck "Medication Guide - Victrelis™" http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_mg.pdf. Retrieved May 18, 2011.

Merck "Patient Assistance Programs" http://www.merck.com/responsibility/pap-information.html. Retrieved May 23, 2011.

Neutropenia Support Association, Inc. "What is Neutropenia?" http://www.neutropenia.ca/. Retrieved May 19, 2011.

Victrelis http://victrelis.com/boceprevir/victrelis/consumer/index.jsp. Retrieved May 23, 2011.